since its introduction in the 1940s for use in patients with rheumatoid arthritis. Received wisdom holds that in ulcerative colitis the reduction of the azo bond by colonic bacteria releases the active moiety of sulphasalazine, 5 aminosalicylic acid (5ASA) which acts topically, and sulphapyridine which is rapidly absorbed causing side effects. Various pharmacological means have been developed for delivering pure 5ASA to the colon since uncoated 5ASA is rapidly absorbed and is thus ineffective. Three The side effects of sulphasalazine (incidence 15-30%) are dose dependent (dyspepsia, nausea and vomiting, headache, and reversible oligospermia) or idiosyncratic (fever and neutropenia, inflammatory reactions affecting lung, liver, myocardium, and pancreas).3 Pure SASA preparations by eliminating sulphapyridine should prevent these unwanted effects. Adverse responses to sulphasalazine, however, have also been seen with 5ASA products, although at least 70% of sulphasalazine intolerant patients will find 5ASA products acceptable. 4 Changing the delivery system from an azo bond to mechanical or pH dependent release has two important implications. Firstly, it reduces the effectiveness of colonic 5ASA delivery from 80-98% to 40-95% and, secondly, it alters SASA pharmacokifletips. The ethylcellulose coating of Pentasa granules dissolves gradually during passage through the small bowel' while the resin coating of Asacol may allow for rapid release of free 5ASA (at an appropriate pH). Free 5ASA is acetylated both in the small bowel6 and colonic epithelium.7 In the small bowel this process can be overloaded by rapid release of 5ASA. This allows appreciable amounts of non-acetylated 5ASA to be absorbed, which is clearly nephrotoxic in experimental animals, while acetylated 5ASA is not.8 4 Aminosalicylic acid (para aminosalicylic acid previously used in the tr'eatment of tuberculosis) and phenacetin were important causes of crystalluria, haematuria, and nephritis; the structure and metabolism of these drugs are closely similar to non-acetylated SASA. Recent Early studies showed a dose-response relation between sulphasalazine and its efficacy in moderately active disease'4 and in maintaining remission2 with daily doses of between 1 and 18 g. '7 Because of dose dependent side effects a compromise of giving 4 g daily for active disease and 2 g for maintenance treatment is common, providing 1600 mg and 800 mg 5ASA respectively. If sulphasalazine is merely delivering SASA to its site of action it should follow that the higher the local concentration of SASA the more effective the treatment. While, however, studies have shown 5ASA compounds to be as effective as therapeutic doses. (3-4 g ) of sulphasalazine none has been superior even with doses of SASA equivalent to 12 g sulphasalazine, suggesting there is more to the action of sulphasalazine than SASA.
In rheumatoid arthritis the sulphapyridine component of sulphasalazine has been shown to have disease modifying (immunomodulatory) activity,'5 requiring at least six weeks to take effect; nevertheless, it is precisely the systemic and delayed onset of action of sulphapyridine that has not been studied in patients with ulcerative colitis in contrast to its documented inefficacy when given topically in the short term. '6 It is interesting to compare the actions in vitro of sulphasalazine and 5ASA on the inflammatory cascade. After tissue damage there is disruption of cell membranes with release of arachidonic acid, the fate of which is determined by the relative activity of cyclo-and lipoxygenase. The former generates prostaglandins, which may promote healing, the latter produces leucotrienes, which are potent neutrophil chemoattractants and vasoconstrictors and may cause further damage. There is appreciable overproduction of leucotrienes in active disease and some increase in concentrations of prostaglandins.'8 Work in vitro suggests that therapeutic concentrations of sulphasalazine inhibit lipoxygenase more potently than 5ASA.'9 In contrast, both agents block cyclooxygenase (a potentially serious effect seen in exacerbations ofinflammatory bowel disease after ingestion ofnon-steroidal anti-inflammatory drugs).20 Sulphasalazine mediated inhibition of prostaglandin degradation, however, causes a net increase in tissue prostaglandin level concentrations2' and thus promotes healing.
Neutrophils are the chief effector cell in tissue destruction in ulcerative colitis, causing damage by lysosome release and the generation of damaging oxygen free radical species. The use of steroids delayed the widespread adoption of sulphasalazine in rheumatoid arthritis for over 30 years.28 Before sulphasalazine is discarded as an outmoded treatment for ulcerative colitis in favour of more modern 5ASA compounds, a greater understanding is needed of the ways in which these drugs work, lest in throwing out the bathwater we lose rather more of the baby than expected. 
